Phase II trial of temsirolimus in patients with metastatic breast cancer

Preclinical models suggested that activating mutations of the PIK3CA gene are associated with sensitivity to inhibitors of the mammalian target of rapamycin (mTOR). In breast cancers, PIK3CA mutations are associated with estrogen receptor (ER) positivity. We therefore performed an open-label single...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fleming, Gini F., Ma, Cynthia X., Huo, Dezheng, Sattar, Husain, Tretiakova, Maria, Lin, L., Hahn, Olwen M., Olopade, F. O., Nanda, R., Hoffman, Philip C., Naughton, M. J., Pluard, Timothy, Conzen, Suzanne D., Ellis, Matthew J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3658119/
https://ncbi.nlm.nih.gov/pubmed/22245973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-011-1910-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados